吉非替尼治疗老年晚期非小细胞肺癌的临床研究

Clinical Observation of Gefitinib for Senile Advanced Non-small Cell Lung Cancer

目的探讨吉非替尼治疗老年晚期非小细胞肺癌(NSCLC)患者的疗效及安全性。方法31例65岁以上Ⅳ期非小细胞肺癌患者,给予吉非替尼(商品名IRESSA()250 mg,口服,1次/d,持续用药至病情进展或死亡,电话随访,每月1次。结果全部患者均可进行疗效评价,其中CR 1例,PR 9例,SD 14例,PD 7例,有效率(CR+PR)32.3%。疾病控制率77.42%,患者的ZPS提高(2.0±0.2)分,P<0.05。随访截止,有21例患者存活,全部有效患者的中位生存时间(MST)13.5个月;10例死亡,死亡患者的MST为5.8个月,疾病进展时间(TTP)为3.4个月。仅有轻微皮肤和消化道反应。结论吉非替尼治疗老年晚期非小细胞肺癌患者疗效确切,耐受性好。

Objective To evaluated the efficacy and toxicity of Gefitinib in treating senile advanced non-small cell lung cancer （NSCLC）. Methods Thirty-one elderly patients with NSCLC of stage Ⅳ were enrolled in the study, which was administered orally Gefitinib at a dose of 250 mg/d until the disease was improved or death. The follow-up was carried out with telephone once a month. Results All 31 patients were evaluable for therapeutic effect. The overall response rate was 32.3%, in which CR 1 case,PR 9 cases, SD lg cases and PD 7 cases. The rate of symptom improvement was 77.42% for all patients. The Zubrod- ECOG-WHO performance status（ZPS） was improved（2.0 ±0.2 ） after the treatment（ P 〈 0.05 ）. The follow-up showed that there were 21 patients still alive, and the MST of all effective patients was 13.5 months. 10 patients were dead, and the MST and TIP was 5.8 and 3.4 months. No severe toxicity was observed. Conclusion Gefitinib is effective and safe for senile advanced NSCLC.